BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Europabio
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210930T140000
DTEND;TZID=Europe/Brussels:20210930T150000
DTSTAMP:20260526T231434
CREATED:20210614T154210Z
LAST-MODIFIED:20211001T075124Z
UID:2727-1633010400-1633014000@www.europabio.org
SUMMARY:The small companies changing the world: Meet the science and business of sustainability
DESCRIPTION:With the Green Deal\, the EU has set an ambitious strategy towards climate neutrality\, transitioning to a circular economy and a more sustainable food system. Many aspects of our lives must change to achieve these ambitions: a reduction in only high profile targets\, such as transport\, will not be enough. Our food\, cosmetics\, clothes\, and other products and consumables across our lives need to get leaner and greener and biotechnology solutions can contribute towards responding to this need. \n\n\n\nConfirmed speakers: \n\n\n\nJuan Medina\, Co-Founder and CEO Kaffe BuenoTaichi Ochi\, Senior Business Developer\, EV BiotechCyrille Pauthenier\, CEO Abolis\n\n\n\nJoin us to find out how small companies across Europe are rising to the challenge to innovate for our sustainable futures. \n\n\n\n\nSlides\n\n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/the-small-companies-changing-the-world-meet-the-science-and-business-of-sustainability/
CATEGORIES:Biotech Week
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/06/European-Biotech-Week-Event-Banner-4.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210929T120000
DTEND;TZID=Europe/Brussels:20210929T133000
DTSTAMP:20260526T231434
CREATED:20210614T150425Z
LAST-MODIFIED:20210929T123032Z
UID:2723-1632916800-1632922200@www.europabio.org
SUMMARY:Investing in healthcare - How can the revision of the general pharmaceutical legislation better attract investors in the future?
DESCRIPTION:The evaluation and revision of the general pharmaceutical legislation is the opportunity to create a future-proof\, patient-oriented and leading life science and biotechnology sector in the EU. \n\n\n\nThe first aim of this initiative should be to regain EU’s global leadership as a home for R&D and cutting-edge industry to secure high-quality care for citizens at affordable levels. \n\n\n\nNew biotechnology-derived vaccines and treatments have helped to tackle numerous life-threatening illnesses. Targeted treatments\, like cell and gene therapies\, and new mRNA platforms are paving the way for future treatments. COVID-19 has shown that only science-based and high-risk research embedded in a strong life science industry ecosystem can bring the lasting solutions to health challenges. \n\n\n\nEmerging biopharmaceutical companies account for over 70% of the research pipeline contributing to a vibrant sector. The EU biotech sector\, mostly made up of SMEs\, relies on robust IP and targeted incentives that enable companies to raise risk capital\, with the prospect of remaining unprofitable for years. It is due to these set of incentives that the EU has retained its capability to produce breakthrough innovation. To keep pace with the rest of the world\, future incentives should reflect the economic challenges of developing health innovation. \n\n\n\nJoin us to find out how investing in R&D for innovative medicines and treatments is essential to support a competitive European biotechnology industry. \n\n\n\nConfirmed speakers:: \n\n\n\n\nJuozas OLEKAS\, Member of the European Parliament\, S&D\, Lithuania \n\n\n\nStefan Gijssels\, SEBOIO Health Policy Consulting and Co-founder of digestive Cancer Europe \n\n\n\nIngrid Maes\, Co-founder of Inovigate\, 25 years of experience in Life Sciences Expertise in New Product Development and Market Introduction \n\n\n\nIsabelle Schubert\, Global Head IP Strategy at Novartis \n\n\n\nOskar Slotboom\, General Partner at BGV (BioGeneration Ventures) \n\n\n\n\nSlides\n\n\n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/investing-in-healthcare-how-can-the-revision-of-the-general-pharmaceutical-legislation-better-attract-investors-in-the-future/
LOCATION:Invest Europe
CATEGORIES:Biotech Week
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/06/European-Biotech-Week-Event-Banner-1-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210927T153000
DTEND;TZID=Europe/Brussels:20210927T170000
DTSTAMP:20260526T231434
CREATED:20210614T145612Z
LAST-MODIFIED:20210922T105308Z
UID:2714-1632756600-1632762000@www.europabio.org
SUMMARY:Biotechnology for society - Turning science into a sustainable and healthy world
DESCRIPTION:EuropaBio’s launch meeting for Biotech Week will share how science finds its way to an end use\, whether it is a new medicine\, or a product developed using new scientific processes.  \n\n\n\nEurope sets the global standard for consumer and environmental protection.  This translates into a regulatory framework for different sectors through which novel products must pass before they can be used in Europe.  The European Medicines Agency (EMA) and the European Food Safety Authority (EFSA) are the gateway for new products and play a critical role in how Europe innovates safely. \n\n\n\nIt can be complicated\, particularly for new science. So how does Europe deliver innovation to benefit patients and our planet whilst ensuring the high standards and safety that we expect? \n\n\n\nThe Covid response from regulators demonstrated how Europe can be agile and rapid for the vaccines that are now helping Europe restore a safe and open society.  Our launch event for Biotech Week brings together the community that develops products from science to consumers\, highlighting how we can evolve our regulatory systems help develop safe societies and a competitive Europe. \n\n\n\nConfirmed speakers: \n\n\n\nAna Maria Bravo\, Director of Government Affairs\, IFFWolfgang Gelbmann\, Senior Scientific Officer\, Nutrition Unit\, EFSADamian Gilkerson\, CSL Behring Executive Director Therapeutic Area EU\, Commercial Operations EuropeEmmanuelle Voisin\, CEO Voisin Consulting Life Sciences\n\n\n\nJoin us to find out how science reaches its target and help EuropaBio kick start a week dedicated to the explanation and celebration of biotechnology. \n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/biotechnology-for-society-turning-science-into-a-sustainable-and-healthy-world/
CATEGORIES:Biotech Week
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/06/European-Biotech-Week-Event-Banner-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210927T120000
DTEND;TZID=Europe/Brussels:20211001T120000
DTSTAMP:20260526T231434
CREATED:20210401T124400Z
LAST-MODIFIED:20210401T124400Z
UID:1932-1632744000-1633089600@www.europabio.org
SUMMARY:10th International Trade Show & Partnering
DESCRIPTION:The largest biotech event country based event in Europe \n\n\n\nBIOSPAIN is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings (+3.300) and companies participating (+773). 34% of our delegates came from outside of Spain. \n\n\n\nWhy Spain? \n\n\n\nIn 2018 there were 751 dedicated biotechnology enterprises in Spain (+5\,33%)\, according to data in the AseBio Report 2019. Biotech companies have generated more than €8.2 billion in income\, roughly 0.7% of the national total. The biotechnology sector was responsible for more than 105\,000 direct\, indirect and induced jobs\, which is 0.6% of national employment. Over 27\,000 of these jobs were people employed directly by biotech companies. Biotechnology activities are at the top of rankings on production growth of economic activities for 2018\, up 10.1%.” \n\n\n\nEuropaBio Members can benefit of a 10% discount on the price. Please liaise with Martina Cilia (m.cilia@europabio.org) to receive detailed information on the discount code. \n\n\n\n\nRegister here
URL:https://www.europabio.org/event/10th-international-trade-show-partnering/
LOCATION:Auditorium & Trade Show Centre\, Plaza del Baluarte s/n\, 31002\, Pamplona\, Spain
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/04/Event-Banners.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210927T080000
DTEND;TZID=Europe/Brussels:20211003T080000
DTSTAMP:20260526T231434
CREATED:20210128T134240Z
LAST-MODIFIED:20210610T122254Z
UID:948-1632729600-1633248000@www.europabio.org
SUMMARY:European Biotech Week 2021
DESCRIPTION:The European Biotech Week celebrates biotechnology\, an innovative and vibrant sector launched by the discovery of the DNA molecule back in 1953. The first European Biotech Week that took place in 2013 marked the 60th anniversary of this pivotal moment in history. \n \n 
URL:https://www.europabio.org/event/european-biotech-week-2021/
CATEGORIES:EuropaBio,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/European-Biotech-Week-Event-Banner-.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210921T143000
DTEND;TZID=Europe/Brussels:20210921T153000
DTSTAMP:20260526T231434
CREATED:20210831T112430Z
LAST-MODIFIED:20210922T093101Z
UID:3028-1632234600-1632238200@www.europabio.org
SUMMARY:EFIB Pre-event webinar
DESCRIPTION:Sustainability in industrial biotech innovations: life cycle assessment and beyond \n\n\n\nSponsored by DSM\n\n\n\n \n\n\n\n\n\nGet ready for EFIB 2021 by attending the kick-off webinar “Sustainability in Industrial biotech innovations: Life Cycle Assessment and beyond”\, which will take place on Tuesday 21 September 2021 from 14.30 – 15.30 CET. \n\n\n\nSustainability is the drive and purpose behind most industrial biotech innovations. But how to incorporate it in the innovation process? How to assess it\, measure it\, and use it for decision making? During this webinar we will explore: \n\n\n\n• How well-established tools like Life Cycle Assessment are being used in industrial biotech innovations \n\n\n\n• What are novel tools and methodologies relevant for the sustainability assessment of industrial biotech \n\n\n\n• How corporates\, start-ups and academia use these tools in their innovation process \n\n\n\nThis kick-off webinar by EuropaBio is co-hosted by Planet B.io\, the open innovation hub for industrial biotechnology\, located at the Biotech Campus Delft in The Netherlands. \n\n\n\nModerator:  \n\n\n\n •  Maria Cuellar-Soares | S&T Officer\, Planet B.io \n\n\n\nSpeakers: \n\n\n\n •  Ulla Létinois | Senior Scientist\, Sustainable Chemistry\, DSM \n\n\n\n •  Yang Xiang | Senior Corporate LCA Expert\, DSM \n\n\n\n •  Cristina Prat | Co-founder\, FUL Foods \n\n\n\n •  John Posada | Assistant Professor in Biotechnology and Society\, TU Delft \n\n\n\n\nSlides\n\n\n\n\nParticipation for this webinar is free of charge\, but registration is required. \n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/efib-pre-event-webinar/
CATEGORIES:EFIB
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/08/Event-Banners.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210920T090000
DTEND;TZID=Europe/Brussels:20210921T170000
DTSTAMP:20260526T231434
CREATED:20210210T200303Z
LAST-MODIFIED:20210628T201352Z
UID:1320-1632128400-1632243600@www.europabio.org
SUMMARY:German Biotechnology Days
DESCRIPTION:Germany’s largest biotech event\, the German Biotechnology Days 2021 (Deutsche Biotechnologietage\, DBT)\, will take place on 20th and 21st September in Stuttgart. With over 800 participants\, the event is regarded as the German class reunion for biotechnology. The DBT brings together entrepreneurs with scientists and partners from politics\, funding institutions and administration. \n\n\n\nIn plenary sessions and numerous symposia\, top-class speakers present and discuss the diverse fields of application and the potential of biotechnology\, from health research to bioeconomy\, from medicine to industrial production and plant breeding. Exchange and networking traditionally play a major role at the DBT. The big evening event on the first day of the conference is therefore a further highlight. In addition to the conference programme\, there will also be a large exhibition. \n\n\n\nThe German Biotechnology Days are jointly organised by BIO Deutschland and the Council of German BioRegions. The host region for 2021 is STERN BioRegion from Stuttgart. As a partner region\, we are looking forward to BioLAGO\, the network for the health industry in the Lake Constance region. \n\n\n\nAbout the organizersBIO Deutschland e. V.\, the industry association of the German biotechnology industry\, and the Council of German BioRegions have been jointly organising the German Biotechnology Days since 2010. The forum for the German biotechnology scene takes place annually at different locations. The regional host of the event is always a bioregion from the Council of German BioRegions\, often accompanied by a partner region. \n\n\n\n\nVIRTUAL EVENT \n \n\n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/german-biotechnology-days/
LOCATION:BIO Deutschland\, Schützenstraße 6a\, Berlin\, D-10117\, Germany
CATEGORIES:External,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-DBT.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210907T160000
DTEND;TZID=Europe/Brussels:20210907T170000
DTSTAMP:20260526T231434
CREATED:20210715T095059Z
LAST-MODIFIED:20210903T072658Z
UID:2936-1631030400-1631034000@www.europabio.org
SUMMARY:Treatment without borders: the EU case for equitable patient access to advanced therapies
DESCRIPTION:The EU Pharmaceutical Strategy is looking to improve patients’ access to therapies for challenging and rare conditions. The EU legislation on cross-border healthcare is an important instrument to ensure patient access to the best available care. There is an urgent need to revise this legislation to enable EU patients to access novel advanced therapies and medicines for rare diseases when these are not available in their home country. \n\n\n\nEuropaBio’s Advanced Therapies Series continues with a virtual discussion on avenues for enhancing the access of EU patients to novel biotechnology-derived treatments on September 7\, 2021\, from 16h00 to 17h00 CET. \n\n\n\nA patient who is also actively engaged in patient advocacy will explain the value of advanced therapies for rare disease patients and the key challenges they encounter when accessing treatments outside their home countries. \n\n\n\nA panel of EU\, national\, and industry representatives will attempt to put forward solutions for securing equitable access to both specialised centres and to treatment for all EU patients in need. Among others\, they will seek to advise on how to tackle the following challenges: some treatment centres being less interested to treat cross-border patients\, the need for experience and expertise in rare diseases\, approval process and time for cross-border treatment\, lack of knowledge or experience of healthcare providers in requesting reimbursement for cross-border treatments\, difficulties in approving advanced therapy applications if not reimbursed in the home country\, etc. \n\n\n\nModerator \n\n\n\nBernard Grimm\, Healthcare Biotech Director\, EuropaBio \n\n\n\nSpeakers  \n\n\n\nJana Popova\, Executive Committee Member of the European Alliance of Neuromuscular Disorders Associations & EUPATI Patient Engagement Training Coordinator \n\n\n\nBrieuc Van Damme\, Director-General Healthcare\, RIZIV-INAMI \n\n\n\nMartin Dorazil\, Deputy Head of Unit\, DG Health\, European Commission \n\n\n\nDirk Vander Mijnsbrugge\, Vice President Medical Affairs Lead Rare Diseases International Developed Markets\, Pfizer \n\n\n\nIrina Grossenbacher\, Region Europe Patient Access Director\, Novartis Rare Diseases \n\n\n\nTomislav Sokol\, Member of the European Parliament\, EPP\, Croatia
URL:https://www.europabio.org/event/treatment-without-borders-the-eu-case-for-equitable-patient-access-to-advanced-therapies/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/07/NL-Size-28.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210906T120000
DTEND;TZID=Europe/Brussels:20210908T120000
DTSTAMP:20260526T231434
CREATED:20210408T113835Z
LAST-MODIFIED:20210408T113835Z
UID:2030-1630929600-1631102400@www.europabio.org
SUMMARY:International Conference on Renewable Resources & Biorefineries
DESCRIPTION:The 17th edition of the International Conference on Renewable Resources & Biorefineries will take place in Aveiro\, Portugal from Monday 6 Sept until Wednesday 8 Sept\, 2021. Based on the previous RRB conferences\, this conference is expected to welcome about 350 international participants from over 30 countries. \n\n\n\nDelegates from university\, industry\, governmental and non-governmental organizations\, and venture capital providers will present their views on industrial biotechnology\, sustainable (green) chemistry\, and agricultural policy related to the use of renewable raw materials for non-food applications and energy supply. The conference further aims at providing an overview of the scientific\, technical\, economic\, environmental\, and social issues of renewable resources and biorefineries in order to give an impetus to the biobased economy and to present new developments in this area. The conference will provide a forum for leading political\, corporate\, academic\, and financial people to discuss recent developments and set up collaborations.The three-day international conference will consist of plenary lectures\, oral presentations\, poster sessions\, and an exhibition. Companies and research organizations are offered the opportunity to organize a satellite symposium. \n\n\n\n \n\n\n\n\nRegister here
URL:https://www.europabio.org/event/international-conference-on-renewable-resources-biorefineries/
LOCATION:University of Aveiro\, Santiago Campus\, 3810-193 Aveiro\, Aveiro\, Portugal
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/04/Event-Banners-3.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210712T090000
DTEND;TZID=Europe/Brussels:20210713T170000
DTSTAMP:20260526T231434
CREATED:20210623T145655Z
LAST-MODIFIED:20210623T150119Z
UID:2771-1626080400-1626195600@www.europabio.org
SUMMARY:EU Matchmaking Event on COVID-19 Therapeutics
DESCRIPTION:Building on the experience of the EU Task Force for Industrial Scale-up of COVID-19 vaccines\, the European Commission will facilitate cooperation between actors in the supply chain to ensure that available therapeutics are produced in sufficient quantity as soon as possible. In the context of a surge in demand\, it remains crucial to ensure the speedy production of current and new therapeutics against COVID-19. To support the industry\, the Commission organises the pan-EU matchmaking events for all supply chain actors\, so that they find solutions for the bottlenecks encountered. \n\n\n\nMedicines for COVID-19 are still in the development phase. Therefore\, the objective of the event is to help accelerate the development of new and repurposed medicines for COVID-19 therapeutics\, i.e. medicines specifically developed for an indication in treatment of COVID-19\, at all stages of COVID-19 disease and mobilise the EU pharma manufacturing capacity for their potential production. \n\n\n\nThe target group is the entire EU COVID-19 therapeutics value chain starting with researchers and developers\, through manufacturing companies and representatives of the hospitals\, who apply such therapeutics to their patients. The providers of ancillary functions such as clinical trials services\, accessories suppliers (e.g. vials\, syringes\, tubes etc.)\, funding providers and public procurers will also be targeted to take part in the event. \n\n\n\nThe event will take place virtually on 12th and 13th July 2021. 12th July will start with a half-day seminar setting the scene with a welcome by Commissioner Breton and Commissioner Kyriakides. \n\n\n\n\n\n\n\nHow to apply? \n\n\n\nIn order to apply to the event\, European companies must comply with the requirements stated in the event’s Call for Expression of Interest. Register until June 25.
URL:https://www.europabio.org/event/eu-matchmaking-event-on-covid-19-therapeutics/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2021/06/European-Matchmaking-event-e1624460170563.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210630T121500
DTEND;TZID=Europe/Brussels:20210630T134500
DTSTAMP:20260526T231434
CREATED:20210609T145626Z
LAST-MODIFIED:20210611T110808Z
UID:2648-1625055300-1625060700@www.europabio.org
SUMMARY:Changing Global Ambitions for Biotechnology Innovation: Implications and Drivers for Europe
DESCRIPTION: \nEuropaBio hosts a member-only discussion session looking at ambitions for innovation and business in China\, and how this impacts both the EU and US. We are delighted to welcome McKinsey’s China office to the meeting\, where they will present an inside look at changing Chinese ambitions for industrial growth from innovation.\n \nMember discussion then focuses on how Europe can deliver its own ambitions in a world where changes beyond its borders will influence success\, and how it needs to develop a strong and realistic economic vision for technology from companies and governments.\n \nEuropaBio looks forward to an interesting cross-sector debate amongst Members on the long-term future of Europe as a global competitor and economic performer within the technology space\, within profound economic changes world-wide.\n \nAll members are eligible to attend and should contact EuropaBio (m.cilia@europabio.org) if they have not yet received an invitation.
URL:https://www.europabio.org/event/changing-global-ambitions-for-biotechnology-innovation-implications-and-drivers-for-europ/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/06/Event-Banners-25.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210610T120000
DTEND;TZID=Europe/Brussels:20210618T120000
DTSTAMP:20260526T231434
CREATED:20210408T080837Z
LAST-MODIFIED:20210408T081528Z
UID:1994-1623326400-1624017600@www.europabio.org
SUMMARY:BIO Digital 2021 - Rise
DESCRIPTION:Accelerating a BIO-Revolution through global partnerships\, collaboration\, and thought leadership. \n\n\n\n\n\n\n\n\n\nJoin The World’s Largest Global Biotech Partnering Experience \n\n\n\nFrom the 10th to June 18th takes place the world’s largest biotechnology partnering event BIO digital 2021\, promoted by the Biotechnology Innovation Organization (BIO). \n\n\n\nThis international convention represents a unique opportunity for companies and institutions related to biotechnology to obtain information of high scientific and financial value\, close strategic alliances\, obtain financing for their projects and get new clients. The event offers an extensive program that includes academic activities\, networking events\, company presentations\, an exhibition area (considered the largest in the world of those specialized in this sector)\, seminars and conferences on new trends in biotechnology and innovations\, among others. \n\n\n\n \n\n\n\n\nRegister here
URL:https://www.europabio.org/event/bio-digital-2021-rise/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/04/Event-Banners-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210603T140000
DTEND;TZID=Europe/Brussels:20210603T150000
DTSTAMP:20260526T231434
CREATED:20210315T132511Z
LAST-MODIFIED:20210602T083815Z
UID:1616-1622728800-1622732400@www.europabio.org
SUMMARY:EU Healthcare Biotech Policy Priorities for SMEs
DESCRIPTION:Join the EuropaBio Healthcare Biotechnology Team for a dive into EU policies that impact your current operations and will shape your future strategies. With the ongoing revision of the basic pharmaceutical legislation and of regulations for medicines for rare and paediatric diseases\, SMEs should be planning how they build and grow their businesses\, whether within the EU or outside. \n\n\n\nAbout the EuropaBio SME Platform \n\n\n\nThe SME platform is a community of SMEs across all sectors in Europe\, supported through regular online meetings around EU-level topics that impact commercial biotechnology and represented to EU stakeholders. \n\n\n\n  \n\n\n\n\nREGISTER HERE\n\n\n\n\n\n\n\n\n 
URL:https://www.europabio.org/event/eu-healthcare-biotech-policy-priorities-for-smes/
CATEGORIES:EuropaBio,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-9-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210602T090000
DTEND;TZID=Europe/Brussels:20210603T170000
DTSTAMP:20260526T231434
CREATED:20210209T180700Z
LAST-MODIFIED:20210308T093844Z
UID:1303-1622624400-1622739600@www.europabio.org
SUMMARY:Global Access to Innovations in Healthtech (GAINH) Summit
DESCRIPTION:The Global Access to Innovations in Healthtech Summit is a biennial EXCITE International summit\, a Canada based not-for-profit initiative. The 2021 edition will be organized in collaboration with HI-NL\, a Dutch organization. \n\n\n\nGAINH 2021 will be the first edition taking place in Europe. \n\n\n\nThe biennial summit has a unique approach that engages industry\, payers\, health systems\, expert end-users and patients across the full pathway\, from innovation to adoption\, bringing these technologies to market with greater certainty and at a lower cost. \n\n\n\nTogether with HI-NL\, EXCITE International will bring the European and American markets together to accelerate the pathway from innovation to adoption. \n\n\n\nAbout the organizers \n\n\n\nEXCITE International and Health Innovation Netherlands (HI-NL) closely collaborate to work towards the common goal of helping innovative medical technologies become accessible to patients\, civilians and care providers through a more timely and streamlined process of evaluation\, market access\, implementation\, adoption and reimbursement. \n\n\n\nThis is achieved by ensuring that all relevant stakeholders who are involved in the life cycle of medical technology\, are as early as possible involved in this process. Both organizations are focused on changing the landscape of the medical technology space and believe that innovative ideas that are transformed into medical technological innovations\, have the power to shift the patient\, civilian and care provider experiences. \n\n\n\nThrough their collaboration\, EXCITE International and HI-NL are creating the bridge between the North American and European medical technology sectors\, where stakeholders and their experiences can easily be exchanged. \n\n\n\n\n\n\n\n(GAINH 2021 is organized by Hyphen Projects\, a specialized project office that initiates\, develops and organizes career fairs\, networking events\, websites and other formats for the Life Sciences and related sectors).
URL:https://www.europabio.org/event/global-access-to-innovations-in-healthtech-gainh-summit/
LOCATION:VIRTUAL\, Veerstraat 37\, Hilversum\, 1211 HJ\, Netherlands
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-GAINH.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210527T130000
DTEND;TZID=Europe/Brussels:20210527T143000
DTSTAMP:20260526T231434
CREATED:20210511T134921Z
LAST-MODIFIED:20210528T100244Z
UID:2445-1622120400-1622125800@www.europabio.org
SUMMARY:EFIB 2021 Kick-Off Webinar - How to accelerate biotech innovation for a sustainable future
DESCRIPTION:Get ready for EFIB 2021 by joining our launch webinar “How to accelerate biotech innovation for a sustainable future”. \n\n\n\n EuropaBio is pleased to announce this kick-off webinar\, co-hosted by DSM and Planet B.io\, both located at the Biotech Campus Delft. The webinar will feature industry\, start-up\, and financing perspectives on the European biotechnology innovation ecosystem.  \n\n\n\nIt will provide insights on recent developments in the field\, discuss cooperation in the field and have an outlook on what to expect at EFIB 2021 in Vienna this year.  \n\n\n\nSpeakers:\n\n\n\n– Claire Skentelbery – General Director\, EuropaBio– Cindy Gerhardt – Managing Director\, Planet-B.io at the Biotech Campus Delft– Rob van der Meij – Partner\, Capricorn Partners– Amadeus Driando Ahnan-Winarno – Co-Founder & Head of Technology\, Better Nature \nYou can watch the video recording here\, or download the speakers’ presentations here. \n\n\n\n\n\n\n\n\n\n\nREGISTER HERE\n\n\n\n\n\n\n\n\n\n\n 
URL:https://www.europabio.org/event/efib-2021-kick-off-webinar-how-to-accelerate-biotech-innovation-for-a-sustainable-future/
CATEGORIES:EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2021/05/Event-Banners-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210520T140000
DTEND;TZID=Europe/Brussels:20210520T150000
DTSTAMP:20260526T231434
CREATED:20210421T071455Z
LAST-MODIFIED:20210517T090546Z
UID:2157-1621519200-1621522800@www.europabio.org
SUMMARY:Then and Now – Delivering a Successful Therapeutic to Patients
DESCRIPTION:In today’s whirlwind of diagnostics\, vaccines and therapeutics\, we take a step back and look at how the world of development and manufacturing of biologics has evolved over the last 25 years\, bringing together EuropaBio Members and 25th Anniversary Sponsor\, Catalent.We look back at changing experience from the last quarter of a century in the pathway to patients\, plus how the latest advanced technologies translate into effective pre-clinical and clinical development and manufacturing. Hear expert presentations from EuropaBio Members and Catalent Biologics\, before a detailed Q&A session with the audience on all aspects of developing a successful biologic in 2021. \n\n\n\nAspects to be discussed include: \n\n\n\nWhat trends are driving growth in the pharma industry\, and how are next generation therapies addressing previously unmet needs?As advanced technologies travel through the pipeline\, how are pharma companies\, CDMOs and other partners able meet their complex and novel requirements?In a global world\, how do you embrace and integrate skills and capacity from multiple sites\, often in different continents?As complex\, advanced medicines become reality\, how do you work with regulators from the earliest stages of pre-clinical development to enable a smooth pathway to clinic and market?\n\n\n\nFEATURED SPEAKERBehzad Mahdavi\, Ph.D.​Vice President of Open Innovation\, Biologics\, Cell and Gene Therapy \n\n\n\nMartine Lewi\,​Scientific Director\, Janssen R&D/Clinical Innovation \n\n\n\n \n\n\n\nWith over 20 years’ experience in developing and implementing impactful growth strategies in the biopharmaceutical industries\, Dr. Mahdavi joined Catalent in 2020 after a 13-year career at Lonza\, where he held the role of Vice President Strategic Innovation & Alliances\, and various board-level positions at other innovative companies. Prior to joining Lonza\, he was Chief Executive Officer of SAM Electron Technologies\, a venture capital-backed company in the life sciences field. He holds a doctorate in chemistry from the University of Sherbrooke\, Canada\, and also has a master’s in business administration from the University of Quebec in Montreal. \n\n\n\nJoin this webinar co-organised by Catalent and EuropaBio in the framework of EuropaBio 25th Anniversary and take part to the celebrations!  \n\n\n\n \n\n\n\n \n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/then-and-now-delivering-a-successful-therapeutic-to-patients/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/04/Catalent-Webinar.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210518T103000
DTEND;TZID=Europe/Brussels:20210518T143000
DTSTAMP:20260526T231434
CREATED:20210324T082247Z
LAST-MODIFIED:20210427T094258Z
UID:1606-1621333800-1621348200@www.europabio.org
SUMMARY:EuropaBio Patient BioForum: Advancing patient access to innovative treatments
DESCRIPTION:2021 is set to be another landmark year in the area of health. It is hoped to not only relieve the burden of the COVID-19 pandemic on EU patients and healthcare systems\, but also let the health community advance the great number of other priorities there are. In the EU\, 2021 is set to give a start to the implementation of the European Health Union and the related objectives of the new EU Pharmaceutical Strategy. Among these\, the EU health community is looking to improve patients’ access to therapies for challenging and rare conditions. \n\n\n\nThis meeting of EuropaBio’s Patient BioForum will discuss avenues for enhancing the access of EU patients to novel biotechnology-derived treatments in two sessions: \n\n\n\nMorning session – 10:30-12:00 CET\n\n\n\nPharmaceutical Strategy implementation for continued innovation and delivery in the area of rare and paediatric diseases. \n\n\n\nThe European Commission is discussing on the calibration of incentives for investing in the development of medicines for rare and paediatric diseases both with Member States and stakeholders. We invite the BioForum members to exchange proposals for informing this important debate on several key points\, such as criteria for defining unmet need and incentivising innovation in such areas\, etc. \n\n\n\nAfternoon session – 13:00-14:30 CET\n\n\n\nImproving patient access across borders \n\n\n\nThe EU Directive on cross-border healthcare is an important instrument to ensure patient access to the best available care. The Directive is particularly relevant for advanced therapies and medicines for rare diseases. Well-functioning EU cross-border healthcare legislation can ensure patients have access to specialised treatments and novel therapies when these are not available in their home country. \n\n\n\nThe exchange between guest speakers and BioForum members is aimed to result in the post-meeting release of policy recommendations for how patient access can be advanced in the EU in the context of its new Pharmaceutical Strategy. \n\n\n\nWe very much look forward to your active participation on 18 May 2021.  \n\n\n\n \n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/europabio-patient-bioforum-advancing-patient-access-to-innovative-treatments/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210518T090000
DTEND;TZID=Europe/Brussels:20210520T170000
DTSTAMP:20260526T231434
CREATED:20210210T205019Z
LAST-MODIFIED:20210212T162627Z
UID:1353-1621328400-1621530000@www.europabio.org
SUMMARY:Renewable Materials Conference
DESCRIPTION:Featuring a unique concept to present all sustainable and renewable material solutions at one event: bio-based\, CO2-based and recycled. This time\, the conference will be held as hybrid event. 300 to 400 participants are expected. \n\n\n\nThere is a growing market demand for advanced and ready-to-use sustainable material solutions with a low carbon footprint – and fossil-free. As a response to this challenge\, nova-Institute has decided to unite all relevant industries in the new Renewable Materials Conference (RMC). Over three days\, participants get a complete overview of the latest renewable material solutions from a wide range of sustainable raw materials and technologies. \n\n\n\nThe first day will be focusing on building blocks and chemicals\, the second on polymers and plastics and the third on plastic and composite materials. Or in other words: All material solutions based on renewable carbon – avoiding the use of additional fossil carbon. \n\n\n\nThe Renewable Materials Conference is the follow-up event to the “13th International Conference on Bio-based Materials”\, which builds on a successful history of previous conferences: In 2019\, more than 270 participants attended and 30 exhibitors were present. It was the second largest event on bio-based materials in Europe and continues within this new concept. The conference also integrates topics from the “Biocomposites Conference Cologne” and extends the conference with presentations on chemicals and polymers from CO2 use (CCU) as well as new solutions from the field of recycling\, so that the entire spectrum of renewable materials is covered. \n\n\n\nnova-Institute’s renewable carbon approach aims to initiate the end of the fossil age of chemicals and plastics and builds the foundation for the RMC. Renewable chemicals\, plastics\, composites\, fibres and other products can be produced either from biomass\, directly via CO2 utilisation\, or recycling. Naturally\, this includes the established areas of bio-based polymers and biocomposites. \n\n\n\nThe conference will help shape the sustainable future of chemicals and materials and will provide new advantages and synergies by establishing a meeting point for numerous cross-sectoral networking opportunities.
URL:https://www.europabio.org/event/renewable-materials-conference/
LOCATION:NovaInstitute\, Chemiepark Knapsack Industriestraße 300\, Huerth\, 50354\, Germany
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-Renewable-Materials.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210511T120000
DTEND;TZID=Europe/Brussels:20210511T130000
DTSTAMP:20260526T231434
CREATED:20210312T082225Z
LAST-MODIFIED:20210506T121206Z
UID:1571-1620734400-1620738000@www.europabio.org
SUMMARY:Taking health up a gear: value of advanced therapies
DESCRIPTION:Advanced therapies have ground-breaking therapeutic potential\, particularly in disease areas where there is an unmet medical need and available therapeutic options are absent or inadequate. These therapies can bring the possibility of a cure to life-threatening conditions with a one-off treatment\, thereby changing the paradigm of providing health and care to patients suffering serious\, rare or complex diseases. \n\n\n\nA breakthrough innovator in the area of rare diseases will explain the cutting-edge science behind gene therapies\, why they are considered so transformative\, and what promise they hold to addressing unmet patient needs. \n\n\n\nA leading developer of the most innovative cancer treatments – CAR-T cell-based therapies will explain the changing paradigm of providing health for cancer patients and how innovation will help achieve the objectives of Europe’s Beating Cancer Plan. \n\n\n\nThe webinar will also engage policy makers reflecting live on how EU policies can truly harness the ground-breaking potential of advanced therapies. \n\n\n\nSpeakers \n\n\n\nSara Cerdas MEP\, BECA \n\n\n\nDick Sundh\, Head of ACE (Australia\, Canada & Europe) at Kite Pharma\, a Gilead Company  \n\n\n\nDirk Vander Mijnsbrugge\, Vice President Medical Affairs Lead Rare Diseases International Developed Markets at Pfizer \n\n\n\nSimone Boselli\, Public Affairs Director at EURORDIS  \n\n\n\n \n\n\n\nAbout EuropaBio Advanced Therapies Series: \n\n\n\nThe EuropaBio Advanced Therapies series of events\, interviews\, and publications will engage policymakers\, regulators\, patients and their representatives\, developers\, and all relevant stakeholders to discuss how innovation in gene- and cell-based medicine can bring a transformative value for patients. \n\n\n\nThroughout 2021\, we invite you to join us on a journey of exploring the tremendous potential of advanced therapies by discussing the new treatment paradigms\, the future of research and development in this fast-moving space of bio-science\, as well as debating recommendations for improving the access of patients to these ground-breaking treatments and supporting advanced manufacturing\, to name a few. \n\n\n\nVIRTUAL EVENT \n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/taking-health-medicine-up-a-gear-value-of-advanced-therapies/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-10.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210510T150000
DTEND;TZID=Europe/Brussels:20210510T180000
DTSTAMP:20260526T231434
CREATED:20210316T153010Z
LAST-MODIFIED:20210511T074409Z
UID:1593-1620658800-1620669600@www.europabio.org
SUMMARY:Building on biotechnology: From vaccines to economic growth for Europe
DESCRIPTION:EuropaBio National Associations Council\n\n\n\nSummit 2021 – Portugal \n\n\n\n \n\n\n\n\n\n\n\n\n\nEuropaBio’s National Associations Council (NAC) is a platform that brings together all EuropaBio’s National Associations and helps to ensure coordination of EuropaBio actions throughout Europe. The NAC represents biotechnology priorities across Europe’s Member and partner countries\, working together to build long term economic and societal benefit from biotechnology across sectors. \n\n\n\nIn 2021\, the NAC is proud to host its first Summit focussed on priorities for commercial biotechnology development\, delivering the Industrial Strategy within national and European ecosystems. \n\n\n\nThe NAC summit on May 10 will address how we learn from the COVID-19 response\, to enable full societal and economic benefit from biotechnology in the future across sectors. Rapid technology development pathways\, including partnering\, investment and approvals\, created in response to the pandemic have created new\, faster routes to market. Although this was a unique scale and speed for vaccine development\, it shows that biotech can perform quickly and strongly to address unmet issues in healthcare and sustainable development\, creating a solution and also supporting economic recovery across Europe. \n\n\n\nThe EuropaBio NAC Summit is held during the Portuguese Presidency of the Council of EU and organized in collaboration with P-BIO. The outcomes from the Summit will include a EuropaBio NAC Position on building economic pathways from biotech post-Covid with the role of aligned and ambitious national policies and actions. \n\n\n\n \n\n\n\nAgenda\n\n\n\n15:00: Welcome – Claire Skentelbery\, Director General\, EuropaBio \n\n\n\n15:05: Opening remarks – Manuel Heitor\, Minister of Science\, Technology and Higher Education\, Portugal \n\n\n\n15:15: A European ambition in a competitive global landscape. \n\n\n\nWhere biotech and economic ambitions sit within European and global strategies – Claire Skentelbery\, Director General\, EuropaBio \n\n\n\n \n\n\n\n15:30: Session 1 – A new biotechnology ecosystem in Europe \n\n\n\n\nCompanies active in the current response to Covid-19 share how they have built vital collaborations across the biotech-pharma spectrum to deliver breakthrough vaccine technologies to patients at unprecedented speed\, plus how they envision future potential. \n\n\n\n15:30: Economic development driven by Biotech – the Portugal perspective: David Malta\, Founding CEO\, LiMM Therapeutics \n\n\n\n15:45: Developing bio-manufacturing partnerships – Elke Grooten\, Head of EU Relations\, Novartis \n\n\n\n16:00: Pharma-SME collaboration: from innovation to patient\, a global journey – Sinan Atlig\, Regional President IDM\, Vaccines Pfizer \n\n\n\n16:15: Break \n\n\n\n\n16:30: Session 2 – Looking to the future – speed and strength from biotech \n\n\n\nSMEs driving next generation biotechnology present the pathway and challenges to success and highlight what Europe needs to achieve.  EuropaBio National Associations will then discuss the critical framework needed to build further from national and European ecosystem advances from Covid\, accelerating biotech contribution to Europe’s economic development. \n\n\n\nSME drivers \n\n\n\n16:30: The future of vaccines – Bruno Santos\, Co-Founder and CEO\, IMMUNETHEP \n\n\n\n16:40: Reaching all patients for immunity – Kim Kjøller\, CEO\, UNION Therapeutics \n\n\n\nBuilding European strengths \n\n\n\n16:50: Discussion Panel – Associations from across Europe plus audience contributions \n\n\n\nModerator: Claire Skentelbery \n\n\n\nPanellists:  \n\n\n\n– Agne Vaitkeviciene\, Executive Director\, Lithuanian Biotechnology Association \n\n\n\n– Chloe Evans\, Market Research Manager & International Relations\, France Biotech \n\n\n\n– Simão Soares\, President\, P-BIO \n\n\n\n– Hanne Mette Dyrlie Kristensen\, CEO\, The Life Science Cluster (Norway) \n\n\n\n18:00: Summary and Close \n\n\n\nVIRTUAL EVENT \n\n\n\n\nREGISTER HERE\n\n\n\n\nWho should attend? \n\n\n\nThe EuropaBio NAC Summit is open and free of charge.  You should attend if you are active within the development of biotechnology ecosystems at national or European levels\, either as a technology stakeholder (academic or industrial) or a facilitator of technology maturation to market and patients (associations\, tech transfer\, investors\, policy makers…). The event will have a strong discussion element and all participants can be actively involved. The event will also develop preparatory statements for delegate feedback plus post-event discussion on the planned NAC Position. \n\n\n\nDownload below the speakers’ presentations: \n\n\n\nEuropaBio-NAC-Summit-10-May-2021-Slides-FINAL-PDFDownload
URL:https://www.europabio.org/event/building-on-biotechnology-from-vaccines-to-economic-growth-for-europe/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-3.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210428T090000
DTEND;TZID=Europe/Brussels:20210430T170000
DTSTAMP:20260526T231434
CREATED:20210304T110651Z
LAST-MODIFIED:20210429T092459Z
UID:1514-1619600400-1619802000@www.europabio.org
SUMMARY:German Corona Showcase
DESCRIPTION:A considerable part of the global activities for the development and production of diagnostics\, vaccines and drugs against Covid-19 takes place at biotech sites in German-speaking countries. \n\n\n\nThe e-Vent will… \n\n\n\nGive the opportunity to discuss funding\, procurement and governmental supportGive the opportunity to exchange an discuss experiences made with corona researchProvide industry insights and expert views for press representatives and government employee\n\n\n\n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/german-corona-showcase/
CATEGORIES:All
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2021/03/Corona-Showcase.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210422T140000
DTEND;TZID=Europe/Brussels:20210422T150000
DTSTAMP:20260526T231434
CREATED:20210315T132400Z
LAST-MODIFIED:20210409T131755Z
UID:1588-1619100000-1619103600@www.europabio.org
SUMMARY:EU Industrial Biotech Policy Priorities for SMEs
DESCRIPTION:Join the EuropaBio Industrial Biotechnology Team for a dive into EU policies that impact your current operations and will shape your future strategies.  With the Green Deal\, Industrial Strategy\, Circular Economy and many more\, SMEs can take advantage of changes and opportunities to plan and grow their business. \n\n\n\nAbout the EuropaBio SME Platform \n\n\n\nThe SME platform is a community of SMEs across all sectors in Europe\, supported through regular online meetings around EU-level topics that impact commercial biotechnology and represented to EU stakeholders. \n\n\n\n \n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/eu-industrial-biotech-policy-priorities-for-smes/
CATEGORIES:EuropaBio,Industrial Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/SME-April-22-Event-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210422T090000
DTEND;TZID=Europe/Brussels:20210422T101500
DTSTAMP:20260526T231434
CREATED:20210408T075359Z
LAST-MODIFIED:20210412T140755Z
UID:1982-1619082000-1619086500@www.europabio.org
SUMMARY:Think\, Act\, EUnite: A post-COVID-19 paradigm shift in European healthcare
DESCRIPTION:A PUBLIC webinar sponsored by the Novartis EUnite4Health Ecosystem Team \n\n\n\nFor citizens\, industry\, and institutions\, COVID-19 was a stress test that revealed faults in our current health ecosystem. From a less-than-optimal regulatory review and approval processes which limit patient access\, to an industrial manufacturing network that could be improved\, and an R&D ecosystem that is not achieving its full potential\, we have collectively witnessed a health ecosystem ready for evolution. \n\n\n\nAs Europe looks to adopt the “lessons learned” from this crisis\, now is an opportune moment to create change\, discuss opportunities\, and build a future-ready health policy. \n\n\n\nOn behalf of EuropaBio\, JA Europe\, and Novartis\, we are pleased to share a save the date for our Think\, Act\, EUnite: A post-COVID-19 paradigm shift in European healthcare\, PUBLIC webinar to discuss what the future of healthcare in Europe could look like. \n\n\n\nConfirmed speakers include: \n\n\n\nTomislav Sokol\, Member of the European Parliament (EPP\, Croatia) \n\n\n\nSeán Kelly\, Member of the European Parliament (EPP\, Ireland) \n\n\n\nIrene Norstedt\, Director\, People\, DG Research and Innovation (RTD)\, European Commission \n\n\n\nMary Harney\, Former Irish Minister of Health \n\n\n\nBettina Ryll\, Member of the European Commission’s Cancer Mission Board\, Physician and Founder of Myeloma Patient Network Europe \n\n\n\nClaire Skentelbery\, Director-General of EuropaBioKees Roks\, Head of Region Europe\, Novartis Oncology and Member of the European Commission’s Cancer Mission Assembly \n\n\n\nVirtual Event \n\n\n\n\nRegister here
URL:https://www.europabio.org/event/think-act-eunite-a-post-covid-19-paradigm-shift-in-european-healthcare/
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/04/Event-Banners-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210419T090000
DTEND;TZID=Europe/Brussels:20210421T170000
DTSTAMP:20260526T231434
CREATED:20210210T204608Z
LAST-MODIFIED:20210312T150614Z
UID:1347-1618822800-1619024400@www.europabio.org
SUMMARY:Nordic Life Science Days
DESCRIPTION:Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry. Since its inception in 2013\, the event has nurtured a community of people from the world of life science\, and created a unique place to do business. Most attendees express their delight in the informal atmosphere\, combined with an organised approach to meeting highly relevant people. Return visitors come back because they feel they belong to our growing community. \n\n\n\nWe hope to welcome you in Digital format too. We will create live and virtual spaces for meaningful encounters\, with one-on-one meetings being one of the main features of NLSDays. Additionally\, the high quality of topics and presenters provide insight into the most recent trends in science and business. \n\n\n\nNLSDays attracts leading decision makers from biotech\, pharma and medtech as well as finance\, research\, policy and regulatory authorities. \n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/nordic-life-science-days/
LOCATION:SwedenBIO\, Wallingatan 24\, Stockholm\, 111 24\, Sweden
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-NLS.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210415T130000
DTEND;TZID=Europe/Brussels:20210415T143000
DTSTAMP:20260526T231434
CREATED:20210316T094808Z
LAST-MODIFIED:20210318T105028Z
UID:1575-1618491600-1618497000@www.europabio.org
SUMMARY:An EU Vision for Life Science and Biotechnology for a Healthy and Sustainable EU
DESCRIPTION:With the ambitious target to cut greenhouse gas emissions by 55% compared to 1990 levels by 2030 and the EU Green Deal\, the EU has set clear goals to transform the bloc´s economy making it more sustainable while supporting the EU recovery. \n\n\n\nLife sciences and biotechnology remain critical key-enabling technologies for the economy\, generating GDP of over €34.5 billion\, employing 223\,000 people directly in the EU and generating a trade surplus of €22 billion in 2018.  Moreover\, the CO2 mitigation potential of industrial biotech is estimated between 1-2.5 billion tonnes of CO2 equivalent per year by 2030. \n\n\n\nThe Danish life science and biotechnology contributed to the local economy with over €14 billion export of goods and employing around 48\,000 jobs in 2019. Given the importance of this sector for the Danish economy\, the government is working on a new political strategy for the life science sector to succeed the sector’s growth plan implemented in March 2018. \n\n\n\nThe current COVID-19 pandemic has highlighted the need to employ a holistic and strategic approach and exploit synergies among various EU policies\, such as in the areas of research and innovation\, industry and health. Furthermore\, it showed us that the speed at which technologies develop requires that legislation is constantly up-to-date and able to embrace new sustainable innovation. Investing in the transition to a new sustainable economy requires modernised legislation that can support the green transition in the Member States and support the advancement of the EU life science and biotechnology to ensure they continue their main purpose to support the European Union’s ambitious agenda for healthy people and healthy planet. \n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/an-eu-vision-for-life-science-and-biotechnology-for-a-healthy-and-sustainable-eu/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210415T090000
DTEND;TZID=Europe/Brussels:20210416T170000
DTSTAMP:20260526T231434
CREATED:20210210T204147Z
LAST-MODIFIED:20210312T150539Z
UID:1343-1618477200-1618592400@www.europabio.org
SUMMARY:Innovation for Health - Shaping the Future of Healthcare
DESCRIPTION:On 15-16 April 2021\, the 8th edition of Innovation for Health takes place as an online edition with hybrid aspect. Innovation for Health is the meeting place where over 900 bright minds from across Health and Life Sciences come together to shape the future of healthcare. The theme of this year’s conference is immunology\, a topic that\, because of the COVID-19 pandemic\, has never been more relevant. With our energizing programme\, we bring over 40 top-notch speakers to the stage\, display high impact innovations\, highlight best practices\, and demonstrate inspiring developments in healthcare. Inspiring\, interacting\, and networking are at the heart of the conference. Innovation for Health is the leading conference for key players in Health & Life Sciences. \n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/innovation-for-health-shaping-the-future-of-healthcare/
LOCATION:VIRTUAL\, Hyphen Projects - Veerstraat 37\, Hilversum\, 1211 HJ\, Netherlands
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-Innovation-for-Health.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210407T140000
DTEND;TZID=Europe/Brussels:20210407T140000
DTSTAMP:20260526T231434
CREATED:20210308T093624Z
LAST-MODIFIED:20210308T093625Z
UID:1550-1617804000-1617804000@www.europabio.org
SUMMARY:All About RC(I) – Discussing the Renewable Carbon Strategy and Initiative
DESCRIPTION:Discuss the concept of renewable carbon and get answers to all your questions. Get to know the people and companies behind the Renewable Carbon Initiative and learn why your company should join. RCI members Cosun and UPM and nova-Institute will discuss and answer your questions. \n\n\n\nAbout the organizers \n\n\n\nThe Renewable Carbon Initiative (RCI) was initiated by nova-Institute after observing the struggles of the chemical and plastics industry facing the enormous challenges in meeting the climate goals set by the European Union and the sustainability expectations held by societies around the globe. It was clear that the industry has to go beyond using renewable energy. As decarbonisation is not an option for organic chemistry\, which is entirely based on the use of carbon\, an alternative strategy was needed. \n\n\n\n\n\n\n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/all-about-rci-discussing-the-renewable-carbon-strategy-and-initiative-2/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210323T090000
DTEND;TZID=Europe/Brussels:20210324T170000
DTSTAMP:20260526T231434
CREATED:20210210T203214Z
LAST-MODIFIED:20210312T150444Z
UID:1337-1616490000-1616605200@www.europabio.org
SUMMARY:9th Conference on CO2-based Fuels and Chemicals
DESCRIPTION:The conference is one of the oldest and most established worldwide and has developed into a unique meeting place for the entire Carbon Capture & Utilisation (CCU) and Power-to-X industry and its customers. \n\n\n\nThe first day will focus on CO2-based transport and aviation fuels\, the second on CO2-based bulk and fine chemicals. CCU technologies are essential to meet the future demand for carbon from renewable sources. Take a look into the near future and exchange ideas with the leading pioneers. \n\n\n\nCCU is one essential pillar for the supply of renewable carbon besides biomass and recycling. The transition to direct CO2 utilisation as one alternative carbon source is needed to substitute fossil sources\, to fight climate change and to shift towards sustainable and climate-friendly production and consumption. For providing the full benefits of CCU technologies the use of renewable energy is indispensable. Especially the supply of green hydrogen is crucial for the production of CO2-based transportation and aviation fuels\, bulk and fine chemicals. \n\n\n\nA large number of European cross-sectoral projects for hydrogen production via large-scale electrolysers have been announced recently. The European Commission launched a 400 Billion hydrogen strategy for the full energy transition to renewable energies\, as well as for the further use of hydrogen in innovations and technologies such as the production of high-volume synthetic fuels and chemicals. \n\n\n\nMeanwhile\, 100 projects on CO2-based fuel and chemical production\, as well as efficient capture and utilisation technologies have been launched by several start-ups and established companies\, ranging from pilot over demonstration to commercial scale. Even more players show their interest in getting involved in CCU and are increasingly planning and implementing more plants on different scales for Power-to-X technologies\, low carbon fuels and a CO2-based chemistry. Great visions are becoming real business cases and innovations are starting to realise their potential! \n\n\n\nNew and leading players will showcase novel and improved applications based on the use of CO2 as feedstock. Main topics of the conference are green hydrogen production\, carbon capture technologies and carbon utilisation (Power-to-X): Transportation and aviation fuels\, building-blocks\, bulk and fine chemicals as well as advanced technologies for CO2 utilisation such as artificial photosynthesis.
URL:https://www.europabio.org/event/9th-conference-on-co2-based-fuels-and-chemicals/
LOCATION:NovaInstitute\, Chemiepark Knapsack Industriestraße 300\, Huerth\, 50354\, Germany
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-Cologne.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210322T090000
DTEND;TZID=Europe/Brussels:20210325T170000
DTSTAMP:20260526T231434
CREATED:20210210T202010Z
LAST-MODIFIED:20210212T162759Z
UID:1331-1616403600-1616691600@www.europabio.org
SUMMARY:BIO-Europe Spring 2021
DESCRIPTION:The “must-attend” event series has gone digital\, and continues to grow from strength to strength\, proving its importance and relevance to the life science sector. Building on the success and momentum created by BIO-Europe Digital 2020 this past October our upcoming BIO-Europe Spring Digital will deliver more licensing opportunities\, more partnering meetings\, and more hot-off-the-press content than ever.    \n\n\n\nHere’s what will be different for 2021:    \n\n\n\nPRE-RELEASED CONTENT. The digital event will open 5 weeks early with on-demand content (panels\, company presentations and company showcases) to complement your partnering preparations and maximize your digital experience. partneringONE ALL in ONE. Our gold standard partnering platform has been transformed for the virtual era! With ONE login\, you access the entire event. No need to switch back and forth between platforms. Search by company or therapeutic area to discover potential partners and relevant conference sessions and company presentations.ONE SCHEDULE. To satisfy a truly global audience made up of thousands of delegates from more than 55 countries\, we provide one schedule that accommodates ALL TIME ZONES.   SOCIAL NETWORKING OPPORTUNITIES. We understand the value of networking outside of one-to-one meetings. In order to fill that void\, we created the “W
URL:https://www.europabio.org/event/1331/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-Bio-Europe-Spring.png
ORGANIZER;CN="EBD by InformaConnect":MAILTO:EBDcustomerservice@ebdgroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210318T160000
DTEND;TZID=Europe/Brussels:20210318T170000
DTSTAMP:20260526T231434
CREATED:20210128T145930Z
LAST-MODIFIED:20210212T162821Z
UID:957-1616083200-1616086800@www.europabio.org
SUMMARY:KeyGene’s two-part webinar on PanGenomes: needs\, value and applications (part 2)
DESCRIPTION:This two-part webinar on PanGenomes\, which Keygene organizes together with an academic partner and Allen Sessions from BASF\, will explain what one needs to construct PanGenomes and highlight their value in breeding and research. PanGenomes describe the available genetic diversity within\, for instance\, plant species\, crops or germplasm collections. Because of diminishing costs of genome sequencing\, increasing speed of reference genomes construction and advances in bioinformatics\, PanGenomes have become an accessible tool. The genome insights delivered by PanGenomes can spectacularly speed up and contribute to plant breeding and research.
URL:https://www.europabio.org/event/keygenes-two-part-webinar-on-pangenomes-needs-value-and-applications-part-2/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-KeyGene2.png
END:VEVENT
END:VCALENDAR